Fulgent

Aug 04, 2020

•

Jun 30, 2020

Fulgent Q2 2020 Earnings Report

Reported record second quarter results driven by COVID-19 testing demand and growth in traditional genetic testing orders.

Key Takeaways

Fulgent Genetics reported record second-quarter revenue of $17.3 million, a 105% increase year-over-year. GAAP earnings were $3.3 million, or $0.14 per share, and non-GAAP earnings were $4.0 million, or $0.17 per share. The company's growth was fueled by its COVID-19 testing services and a rebound in traditional genetic testing orders.

Record revenue of $17.3 million, a 105% increase year-over-year.

Delivered 180,513 billable tests, a 1003% increase year-over-year.

GAAP earnings of $3.3 million, or $0.14 per share.

Non-GAAP earnings of $4.0 million, or $0.17 per share.

Total Revenue

$17.3M

Previous year: $8.42M